{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:27:10Z","timestamp":1774592830295,"version":"3.50.1"},"reference-count":17,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term survival and outcome were determined for 80 patients with immunoglobulin light chain (AL) amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM\/SCT) more than 10 years ago. Seventeen (21%) patients died within the first year of treatment, of treatment-related complications (14%) or progressive disease (8%). Of the 63 surviving evaluable patients at one year, 32 (51%) achieved a complete hematologic response (CR). For all 80 patients, the median survival was 57 months (4.75 yrs). The median survival exceeds 10 years for patients achieving a CR after HDM\/SCT, compared with 50 months for those not achieving a CR (P &lt; .001). In conclusion, HDM\/SCT leads to durable remissions and prolonged survival, particularly for those patients who achieve a hematologic CR.<\/jats:p>","DOI":"10.1182\/blood-2007-07-099481","type":"journal-article","created":{"date-parts":[[2007,8,2]],"date-time":"2007-08-02T21:17:07Z","timestamp":1186089427000},"page":"3561-3563","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":126,"title":["Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation"],"prefix":"10.1182","volume":"110","author":[{"given":"Vaishali","family":"Sanchorawala","sequence":"first","affiliation":[{"name":"Stem Cell Transplantation Program of the Section of Hematology-Oncology,"},{"name":"Amyloid Treatment and Research Program, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Skinner","sequence":"additional","affiliation":[{"name":"Amyloid Treatment and Research Program, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Quillen","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Program of the Section of Hematology-Oncology,"},{"name":"Department of Pathology and Laboratory Medicine, Boston University School of Medicine; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen T.","family":"Finn","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Program of the Section of Hematology-Oncology,"},{"name":"Amyloid Treatment and Research Program, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe","family":"Doros","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Seldin","sequence":"additional","affiliation":[{"name":"Stem Cell Transplantation Program of the Section of Hematology-Oncology,"},{"name":"Amyloid Treatment and Research Program, Department of Medicine,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111713030742900_B1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis.","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713030742900_B2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"2019111713030742900_B3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1056\/NEJM199704243361702","article-title":"A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.","volume":"336","author":"Kyle","year":"1997","journal-title":"N Engl J Med"},{"key":"2019111713030742900_B4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome.","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"2019111713030742900_B5","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111713030742900_B6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/CCO.0b013e32801494c6","article-title":"Transplantation for amyloidosis.","volume":"19","author":"Gertz","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2019111713030742900_B7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","article-title":"High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.","volume":"140","author":"Skinner","year":"2004","journal-title":"Ann Intern Med"},{"key":"2019111713030742900_B8","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients.","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"key":"2019111713030742900_B9","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"key":"2019111713030742900_B10","article-title":"Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.","author":"Sanchorawala","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2019111713030742900_B11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3816\/CLM.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin Lymphoma"},{"key":"2019111713030742900_B12","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","article-title":"The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).","volume":"105","author":"Palladini","year":"2005","journal-title":"Blood"},{"key":"2019111713030742900_B13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/13506120309041743","article-title":"Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.","volume":"10","author":"Dispenzieri","year":"2003","journal-title":"Amyloid"},{"key":"2019111713030742900_B14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"key":"2019111713030742900_B15","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"2019111713030742900_B16","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2007.25.18_suppl.8050","article-title":"Phase I\/II study of Bortezomib in patients with systemic AL amyloidosis.","volume":"25","author":"Reece","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111713030742900_B17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/10\/3561\/1291178\/zh802207003561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/10\/3561\/1291178\/zh802207003561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T11:44:51Z","timestamp":1587815091000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/10\/3561\/23387\/Longterm-outcome-of-patients-with-AL-amyloidosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,15]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-099481","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1093915.548852","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,15]]}}}